Zum Inhalt springen
Home » Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma –

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of lab-news.de are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu